Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Chondrosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 3temsirolimus 1resiquimod 1poly ICLC 1nilotinib 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1envafolimab 1enasidenib 1TQ-B3525 1Sunitinib 1Nivolumab 1Methotrexate 1Metformin 1Ifosfamide 1HhAntag691 1Epirubicin 1Dacarbazine 1Cisplatin 1Chloroquine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Chondrosarcoma × envafolimab × Clear all
NCT05448820 2023-09-21

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Tracon Pharmaceuticals Inc.

Phase 1/2 Unknown
15 enrolled
Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Chondrosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡